Angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor antagonists have become an important tool for the treatment of hypertension and its cardiovascular complications. Inhibition ...

A new viewpoint article published in the journal JAMA Network in April 2020 deals with the use of a widely used category of cardiovascular medications in COVID-19 patients with hypertension, diabetes, ...

New evidence suggests decreased mortality could outweigh an elevated risk for hyperkalemia in patients heart failure treated ...

The renin–angiotensin system (RAS) is a highly regulated hormonal cascade that plays a central role in the control of blood pressure and the maintenance of renal homeostasis. Its components, including ...

Please provide your email address to receive an email when new articles are posted on . Researchers from the Netherlands have identified benefits and risks associated with stopping renin-angiotensin ...

The renin-angiotensin system (RAS) becomes active at low blood pressure and forms angiotensin II, a hormone that causes blood vessels to constrict, causing blood pressure to rise again. The enzyme ...

Ditching renin-angiotensin system (RAS) inhibitors in advanced chronic kidney disease (CKD) didn't help to slow kidney decline, according to the STOP ACEi trial. These findings were presented at the ...

Circulating tumor cells (CTC) in mesothelioma and its cytomorphological and immunohistochemical correlation with the primary tumor specimens. Fluorodeoxiglucose (FDG)-avidity at positron emission ...

pills Findings may aid physicians in their clinical decision-making in the absence of randomized clinical trial data, according to investigators. Halting renin-angiotensin system (RAS) inhibitors in ...

Please provide your email address to receive an email when new articles are posted on . Click here to read the Cover Story, "For BP management in diabetes, debate continues on optimal definition, ...